Coherus Oncology (CHRS) Other Non-Current Assets (2013 - 2026)
Coherus Oncology (CHRS) posted Other Non-Current Assets of $3.6 million for Q1 2026, down 11.4% sequentially from $4.1 million in Q4 2025, and down 36.51% YoY from $5.7 million in Q1 2025.
Coherus Oncology (CHRS) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Other Non-Current Assets for 14 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 36.51% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (down 36.51% YoY) and the FY2025 annual result came in at $4.1 million, down 94.38% from the prior year.
- Other Non-Current Assets slipped to $3.6 million in Q1 2026 per CHRS's latest filing, from $4.1 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $72.2 million in Q4 2024 and troughed at $3.6 million in Q1 2026.
- A 5-year average of $11.2 million and a median of $7.8 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets surged 645.2% in 2024, then plunged 94.38% in 2025.
- Over 5 years, Other Non-Current Assets stood at $8.7 million in 2022, then increased by 11.74% to $9.7 million in 2023, then soared by 645.2% to $72.2 million in 2024, then slumped by 94.38% to $4.1 million in 2025, then slipped by 11.4% to $3.6 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $3.6 million, $4.1 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | 3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.12 Mn |
| Mar 31, 2026 | 3.59 Mn |
| Dec 31, 2025 | 4.05 Mn |
| Sep 30, 2025 | 4.45 Mn |
| Jun 30, 2025 | 5.04 Mn |
| Mar 31, 2025 | 5.66 Mn |
| Dec 31, 2024 | 72.18 Mn |
| Sep 30, 2024 | 7.38 Mn |
| Jun 30, 2024 | 8.26 Mn |
| Mar 31, 2024 | 9.13 Mn |
| Dec 31, 2023 | 9.69 Mn |
| Sep 30, 2023 | 7.82 Mn |
| Jun 30, 2023 | 7.52 Mn |
| Mar 31, 2023 | 7.83 Mn |
| Dec 31, 2022 | 8.67 Mn |
| Sep 30, 2022 | 9.63 Mn |
| Jun 30, 2022 | 10.15 Mn |
| Mar 31, 2022 | 9.96 Mn |
| Dec 31, 2021 | 10.03 Mn |
| Sep 30, 2021 | 10.26 Mn |